Home / Specialty Pharmacy (page 34)

Specialty Pharmacy

Baxter’s Investigational Hemophilia Drug Succeeds in Phase 3 Study

Today, Baxter International Inc. announced positive results from its late-stage trial evaluating its investigational treatment for patients with hemophilia A or B. The company said that its BAX 817, an investigational recombinant factor VIIa (rFVIIa), demonstrated positive safety and efficacy results in its Phase III clinical trial in patients with …

Read More »

FDNA to Launch Online Forum for the Genetics Expert Community

Pioneer in computer-aided dysmorphology analysis, FDNA, announced that it will launch an online forum for the genetics expert community for undiagnosed and challenging cases. The company said that it will unveil the “Unknown Forum” at the Annual Clinical Genetics Meeting ACMG 2015 in Salt Lake City, UT on March 26, …

Read More »

Study Finds An 80% Colorectal Cancer Screening Rate by 2018 Could Prevent 20,000 Deaths Per Year

Early detection of cancer is critical and can significantly improve survival for most cancer types. Therefore, it is important to utilize screening tools when available. A new study found that increasing colorectal cancer (CRC) screening rates to 80 percent by 2018 would prevent an additional 21,000 colorectal cancer deaths per …

Read More »

Neuralstem’s ALS Drug May be Effective for a Subset of Patients

Today, Neuralstem, Inc. announced top-line data from a mid-stage trial evaluating its investigational amyotrophic lateral sclerosis (ALS) treatment, saying that the drug met its primary safety endpoints. The company said that data from the Phase II trial of NSI-556 spinal cord-derived neural stem cells, under development for the treatment of …

Read More »

Genetic Test Maker 23andMe Hires Biotech Executive to Lead its Drug Development Effort

Google-backed genetic-testing company 23andMe is launching its own drug development unit, and bringing on former Genentech executive to become its chief scientist and lead the company’s research and development efforts. 23andMe has collected genetic information from more than 850,000 customers worldwide from its $99 DNA spit test and more than …

Read More »

Endo Threatens Valeant’s Deal with Competing Bid for Salix Pharmaceuticals

Today, Endo International plc confirmed that it has made a takeover bid for Salix Pharmaceuticals Ltd., looking to interrupt Valeant’s plans to acquire the gastrointestinal drugmaker. Endo said that it has submitted a proposal to the Board of Directors of Salix to acquire all of the outstanding shares of common …

Read More »

Concordia Pays $1.2 Billion for Covis Pharma Assets

Rare disease specialist Concordia Healthcare Corp. recently announced that it will purchase assets of Covis Pharma’s pharma and injectables units for $1.2 billion in cash. Concordia said that it has entered into a definitive agreement to acquire substantially all of the commercial assets of privately held Covis Pharma S.à.r.l and …

Read More »

Merck Serono Partners with Illumina to Develop a University NGS-Based Oncology Diagnostic

Illumina announced that it is partnering with Merck Serono to develop a universal oncology diagnostic that uses next-generation sequencing (NGS). The companies will collaborate to develop a universal NGS-based oncology diagnostic for clinical trials of targeted cancer therapies, with the goal of a more comprehensive tool for precision medicine. The …

Read More »

FDA Approves United Therapeutics’ Rare Pediatric Cancer Drug and Gives the Company a Priority Review Voucher

US health regulators approved the first drug to treat pediatric patients with high-risk neuroblastoma, a rare cancer that develops on immature nerve cells. United Therapeutics Corporation announced that the US Food and Drug Administration (FDA) has approved Unituxin (dinutuximab) Injection, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and …

Read More »

Specialty Therapies Drive Significant Increase in US Drug Spending in 2014

Spending on specialty drugs took a record rise in the US in 2014, largely due to new expensive, yet effective, hepatitis C drugs, according to new data released today in the 2014 Express Scripts Drug Trend Report. According to the pharmacy benefit manager’s (PBM) report, new hepatitis C drugs’ high …

Read More »